Introduction and Scope of Forensic Toxicology

Early forensic toxicology developed around a practical problem: how could an examiner distinguish poisoning from disease and demonstrate the presence of a substance in complex biological material? Mathieu Orfila's Traité des poisons appeared in 1814, and James Marsh introduced his arsenic test in 1836. These are historical milestones, rather than evidence that an old test meets present-day identification requirements.

Classical chemical reactions made otherwise invisible substances observable. They also exposed enduring problems: contaminated reagents, interference from other elements, incomplete extraction and disagreement over interpretation. A deposit or colour change cannot be interpreted without controls and knowledge of what else can produce it.

Chromatography and spectrometric techniques expanded the substances that laboratories could distinguish and measure. Modern instruments can provide much more selective information, but software output is still evidence requiring evaluation. A library suggestion, retention time or ion signal must satisfy the method's identification criteria; apparent precision does not repair an unsuitable specimen.

The history therefore introduces three habits that remain central: test an alternative explanation, document how the observation was produced, and separate the observation from the conclusion. Historical Marsh and Reinsch reactions belong in this context. They are not instructions to generate highly toxic arsenic compounds outside a controlled laboratory.

Toxicology can be organised by the questions asked, the substances studied or the setting in which testing occurs. Clinical, environmental, occupational, analytical and forensic toxicology overlap. There is no single exhaustive four-branch scheme, and a scientist may work across several of these areas.

Forensic work includes post-mortem toxicology, human-performance investigations such as impaired driving, drug-facilitated crime, and other legally relevant testing. Workplace and court-ordered programmes may have separate collection rules, decision thresholds and review processes. A method or cutoff validated for one programme cannot automatically be transferred to another.

Consider a urine result showing a drug metabolite. It may support prior exposure, subject to identification and specimen integrity. Urine alone generally cannot establish a blood concentration at a particular time or the person's level of impairment. The same analytical result can therefore have different usefulness in workplace screening and a driving investigation.

A toxicologist also distinguishes biological testing from seized-substance analysis. Identifying a powder or tablet establishes information about that exhibit; it does not by itself show that a person consumed it. Linking the two requires suitable biological findings and the wider investigation.

Case assessment starts before extraction. The examiner checks the request, case identifiers, seals, specimen labels, collection information and any discrepancy. The referral should provide relevant circumstances, treatment and a clear question without demanding a predetermined conclusion. A leaking container or unclear anatomical source is documented and assessed rather than silently corrected.

The testing plan links the suspected exposure to suitable methods and matrices. A broad drug screen may not include metals, toxic alcohols, carbon monoxide, cyanide, uncommon pesticides or peptide toxins. History can justify additional tests, but an attractive initial hypothesis should not conceal plausible alternatives. Refer a test when the required capability is outside the laboratory's validated scope.

Screening helps direct further work. Identification evaluates whether the evidence sufficiently distinguishes an analyte from alternatives. Quantification measures its amount under a suitable calibration model. These activities can occur within a combined validated method; they do not always require three separate instruments or a fixed two-test sequence.

Quality assurance includes appropriate reference materials, calibrators, blanks and controls, together with checks on contamination, carryover and data integrity. Method validation establishes suitability for the intended application; routine quality control checks whether a particular analytical run performed acceptably. One does not replace the other.

Technical review asks whether the data support the stated result. Interpretation then considers the specimen and case circumstances. A scientifically appropriate conclusion may remain qualified: a substance was identified, but the available evidence is insufficient to estimate the administered dose or assign its contribution to death.

The final report records what was received, what was tested, relevant results and the boundaries of any opinion. Its wording should not turn an unconfirmed screening signal into an identification or a detected substance into a certified cause of death. Supplementary testing, corrections and retained data must remain traceable.

Laboratory organisation varies across countries and services. In the United States, work may be performed by medical-examiner or coroner laboratories, public laboratories, hospitals or independent providers. In the United Kingdom, services and responsibilities depend on the legal system and commissioning arrangement. In India, central and state forensic laboratories and specialist medical services have distinct roles. These are service models, not a universal referral hierarchy.

Choose a provider by the actual question and its demonstrated capability. Relevant considerations include validated analytes and specimen types, reporting limits, quality systems, staff competence, turnaround needs and the availability of specialist interpretation. Accreditation must be checked against its scope; the fact that an organisation holds accreditation does not mean every test it offers is covered.

Published US examples include ANSI/ASB standards for method validation, identification criteria and report content. UKIAFT's 2018 laboratory guidelines provide a separate professional reference. Identify each document's edition and scope: a professional guideline is not automatically a statute, and a draft revision is not the published edition.

Legal requirements vary by jurisdiction. Collection authority, consent, disclosure, expert testimony and evidential admissibility must be checked for the actual case. A national expert-evidence provision does not automatically make a toxicology report admissible or its opinion correct. Detailed national law belongs in a dedicated legal reference, while this introductory lesson teaches the shared scientific workflow.

In a suspected drug-related death, blood concentrations must be considered alongside specimen source, post-mortem interval, decomposition, treatment and pathology. Published therapeutic, toxic and fatal concentration ranges can overlap. They are reference information, not a mechanical rule that assigns cause of death.

For impaired-driving work, timing is central. A specimen collected after the event records a later condition; relating it to earlier behaviour may require assumptions that cannot be verified. A legal threshold, where applicable, answers a specified legal question and should not be presented as a universal biological boundary between impairment and normal performance.

In suspected drug-facilitated crime, prompt appropriate collection can improve the chance of detection. The request should include the reported timing, prescribed medication and treatment. Detection windows depend on the substance, dose, matrix and method. Neither a positive result nor a negative screen establishes consent, the perpetrator or the full sequence of events.

An apparent chemical exposure may require specialist testing beyond a routine drug panel. Carbon monoxide, methanol, pesticides and metals pose different analytical questions. Residues from a scene help develop hypotheses, but a container label cannot establish the identity, concentration or route of exposure in the person.

Post-mortem interpretation is collaborative. The toxicologist explains the analytical findings and their possible significance; the medical examiner, pathologist, coroner or other authorised decision-maker integrates the evidence within the applicable system. Responsibilities vary, and the analytical report should not imply authority that its author does not hold.

A complete investigation also records what remains unknown. An unavailable peripheral-blood specimen, delayed collection, a narrow test panel or uncertain treatment history can materially limit the opinion. Stating that limit is part of the answer, rather than a weakness to conceal.

Specimen selection is developed in Biological, Non-Biological and Viscera Matrices in Toxicology.

Analytical identification is developed in Spectrometric Detection: UV-Vis, FTIR and Mass Spectrometry.

The dedicated Indian statutory reference is Indian Poison Laws: Poisons Act 1919 and Drugs and Cosmetics Act.